NCT06459180 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06459180
Title	A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Acronym	MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20
Recruitment	Recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	Merck Sharp & Dohme LLC
Indications	cervical adenosquamous carcinoma cervical adenocarcinoma cervical cancer cervical squamous cell carcinoma
Therapies	Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Topotecan SKB264
Age Groups:	adult \| senior
Covered Countries	USA \| SWE \| POL \| NOR \| NLD \| ITA \| ISR \| IRL \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG

No variant requirements are available.